2030 Compounding Drug Development 
Drug Patent Watch
DECEMBER 10, 2024
This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. billion in 2022 and is expected to grow at a compound annual growth rate of 5.3% from 2023 to 2030. from 2023 to 2030. References Patheon.
European Pharmaceutical Review
JUNE 28, 2023
million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. Growth of the pharmaceutical and biotechnology industries, plus the need for accurate and precise analytical tools in drug development and quality control are influencing factors. percent between 2023 and 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 17, 2022
According to a recent report , the global formulation development outsourcing market size should grow to $61.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide.
Safe Biologics
JUNE 12, 2023
Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Under the IRA, Medicare will be able to negotiate with drug makers for lower prices on an expanding list of brand-name medications.
Safe Biologics
JUNE 12, 2023
Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Under the IRA, Medicare will be able to negotiate with drug makers for lower prices on an expanding list of brand-name medications.
European Pharmaceutical Review
JULY 24, 2023
A paper published in Pharmaceutics has proposed how a personalised preparation quality assurance programme can achieve this when these products are developed in compounding laboratories. PACMI selects a drug on a quarterly basis. It requests that compounding laboratories adhering to the programme send samples of it.
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. percent between 2022-2030.
Expert insights. Personalized for you.
96 
Let's personalize your content